Furthermore, PSMA radioligand therapy is being evaluated in early-stage PCa patients, such as in patients with smaller lesions or (oligo)metastatic disease (NCT04343885, NCT04297410, NCT04430192, NCT04443062) [10, 12]. This evidence concerns the gene FOLH1 and metastatic neoplasm.